Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANI PharmaceuticalsFRA:BSFA -2.94%78 ROC (Joel Greenblatt) % is 67.08% as of Mar. 2026, which is 268% above its 10-year median of 18.25. GuruFocus rates FRA:BSFA with a GF Score™ of 78/100 and a GF Value™ of €83.99 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 982 Drug Manufacturers companies, ANI Pharmaceuticals ranks better than 86.35% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. ANI Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 67.08%.
The historical rank and industry rank for ANI Pharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:BSFA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27.09 Med: 18.25 Max: 54.78
Current: 54.78
During the past 13 years, ANI Pharmaceuticals's highest ROC (Joel Greenblatt) % was 54.78%. The lowest was -27.09%. And the median was 18.25%.
FRA:BSFA's ROC (Joel Greenblatt) % is ranked better than 86.35% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.28
vs FRA:BSFA: 54.78
ANI Pharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
ANI Pharmaceuticals (FRA:BSFA) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
ANI Pharmaceuticals ROC (Joel Greenblatt) % Related Terms
ANI Pharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for ANI Pharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BSFA vs TRLV, AMLX, XERS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ANI Pharmaceuticals ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's ROC (Joel Greenblatt) % falls into.
ANI Pharmaceuticals ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 67.08% mean?
ANI Pharmaceuticals (FRA:BSFA) has a ROC (Joel Greenblatt) % of 67.08% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ANI Pharmaceuticals and its competitors. This is 268% above median its historical median of 18.25. According to the industry distribution chart, ANI Pharmaceuticals ranks #134 out of 982 companies in the Drug Manufacturers industry, placing it in the top 13.6%.
Is ANI Pharmaceuticals' ROC (Joel Greenblatt) % too high?
ANI Pharmaceuticals' current ROC (Joel Greenblatt) % of 67.08% is 268% above median its 10-year median of 18.25. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.28. ANI Pharmaceuticals' value of 67.08% is 494.7% above this industry median. Based on the distribution chart, ANI Pharmaceuticals ranks #134 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ANI Pharmaceuticals has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ANI Pharmaceuticals' ROC (Joel Greenblatt) % compare to TRLV and AMLX?
According to the Drug Manufacturers industry distribution chart, ANI Pharmaceuticals ranks #134 out of 982 companies for ROC (Joel Greenblatt) %. This places ANI Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.28. ANI Pharmaceuticals' value of 67.08% is 494.7% above this benchmark. While the company's 10-year median is 18.25 vs. the industry median of 11.28, ANI Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.28, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ANI Pharmaceuticals's current ROC (Joel Greenblatt) % of 67.08% is 494.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on ANI Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ANI Pharmaceuticals's current ROC (Joel Greenblatt) % is 67.08%, which is 268% above median its own 10-year median of 18.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ANI Pharmaceuticals (FRA:BSFA) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.99, compared to a current price of €66.00 — trading 21.4% below its estimated fair value. The current ROC (Joel Greenblatt) % is 67.08%, which is 268% above median its 10-year median of 18.25 and 494.7% above the Drug Manufacturers industry median of 11.28. ANI Pharmaceuticals' overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For ANI Pharmaceuticals (FRA:BSFA), the current ROC (Joel Greenblatt) % is 67.08% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANI Pharmaceuticals (FRA:BSFA) Overvalued in 2026?
Based on GuruFocus' analysis, ANI Pharmaceuticals stock appears to be undervalued.
The current stock price of €66.00 is trading 21.4% below its estimated GF Value™ of €83.99.
GuruFocus considers ANI Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for FRA:BSFA:
ROC (Joel Greenblatt) %: 67.08% (268% above median its 10-year median of 18.25)
GF Value™: €83.99 vs. price of €66.00 (21.4% below fair value)
Industry Position: 494.7% above the Drug Manufacturers median (#134 of 982)
No single metric tells the full story. See the FRA:BSFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
78GF Score
Get the complete analysis for FRA:BSFA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BSFA has been successfully added to your 
